Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Rep ; 10(1): 12239, 2020 07 22.
Article in English | MEDLINE | ID: mdl-32699220

ABSTRACT

Lithium (Li) is the cornerstone maintenance treatment for bipolar disorders (BD), but response rates are highly variable. To date, no clinical or biological marker is available to reliably define eligibility criteria for a maintenance treatment with Li. We examined whether the prophylactic response to Li (assessed retrospectively) is associated with distinct blood DNA methylation profiles. Bisulfite-treated total blood DNA samples from individuals with BD type 1 (15 excellent-responders (LiERs) versus 11 non-responders (LiNRs)) were used for targeted enrichment of CpG rich genomic regions followed by high-resolution next-generation sequencing to identify differentially methylated regions (DMRs). After controlling for potential confounders we identified 111 DMRs that significantly differ between LiERs and LiNRs with a significant enrichment in neuronal cell components. Logistic regression and receiver operating curves identified a combination of 7 DMRs with a good discriminatory power for response to Li (Area Under the Curve 0.806). Annotated genes associated with these DMRs include Eukaryotic Translation Initiation Factor 2B Subunit Epsilon (EIF2B5), Von Willebrand Factor A Domain Containing 5B2 (VWA5B2), Ral GTPase Activating Protein Catalytic Alpha Subunit 1 (RALGAPA1). Although preliminary and deserving replication, these results suggest that biomarkers of response to Li may be identified through peripheral epigenetic measures.


Subject(s)
Bipolar Disorder/drug therapy , Bipolar Disorder/genetics , DNA Methylation/drug effects , DNA Methylation/genetics , Lithium/therapeutic use , Biomarkers/metabolism , CpG Islands/drug effects , CpG Islands/genetics , DNA/genetics , Epigenesis, Genetic/drug effects , Epigenesis, Genetic/genetics , Female , Humans , Male , Middle Aged , Retrospective Studies
2.
Sci Rep ; 9(1): 1409, 2019 02 05.
Article in English | MEDLINE | ID: mdl-30723217

ABSTRACT

Midbrain dopaminergic (DA) neurons are involved in diverse neurological functions, including control of movements, emotions or reward. In turn, their dysfunctions cause severe clinical manifestations in humans, such as the appearance of motor and cognitive symptoms in Parkinson's Disease. The physiology and pathophysiology of these neurons are widely studied, mostly with respect to molecular mechanisms implicating protein-coding genes. In contrast, the contribution of non-coding elements of the genome to DA neuron function is poorly investigated. In this study, we isolated DA neurons from E14.5 ventral mesencephalons in mice, and used RNA-seq and ATAC-seq to establish and describe repertoires of long non-coding RNAs (lncRNAs) and putative DNA regulatory regions specific to this neuronal population. We identified 1,294 lncRNAs constituting the repertoire of DA neurons, among which 939 were novel. Most of them were not found in hindbrain serotonergic (5-HT) neurons, indicating a high degree of cell-specificity. This feature was also observed regarding open chromatin regions, as 39% of the ATAC-seq peaks from the DA repertoire were not detected in the 5-HT neurons. Our work provides for the first time DA-specific catalogues of non-coding elements of the genome that will undoubtedly participate in deepening our knowledge regarding DA neuronal development and dysfunctions.


Subject(s)
Chromatin/genetics , Dopaminergic Neurons/metabolism , Mesencephalon/cytology , RNA, Long Noncoding/genetics , Repetitive Sequences, Nucleic Acid/genetics , Animals , Chromatin Immunoprecipitation Sequencing , Female , Male , Mesencephalon/embryology , Mice , Mice, Inbred C57BL , Mice, Transgenic , RNA-Seq , Serotonergic Neurons/metabolism , Transcriptome
SELECTION OF CITATIONS
SEARCH DETAIL